Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

R177

—

a098a002-afa9-5d4d-be82-36988fa3ec93

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.440
  • PROTEIN_SECRETION+0.430
  • OXIDATIVE_PHOSPHORYLATION+0.380
  • TGF_BETA_SIGNALING+0.320
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
  • ADIPOGENESIS+0.260
  • E2F_TARGETS+0.260
  • G2M_CHECKPOINT+0.240
  • MYC_TARGETS_V1+0.230
  • NOTCH_SIGNALING+0.220

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
  • ALLOGRAFT_REJECTION-0.370
  • TNFA_SIGNALING_VIA_NFKB-0.310
  • PANCREAS_BETA_CELLS-0.290
  • COAGULATION-0.260
  • KRAS_SIGNALING_UP-0.250
  • INFLAMMATORY_RESPONSE-0.240
  • KRAS_SIGNALING_DN-0.230
  • IL6_JAK_STAT3_SIGNALING-0.200
  • COMPLEMENT-0.190

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG1213
mng-umap@100
——0.820
210EE3CFC-9230-40BA-9C9F-77949BA763CC
brain-umap@2
——0.819
3R128
bladder-landscape@3
——0.817
4MNG1038
mng-umap@100
——0.800
5TCGA-75-6207-01A-11R-1755-07
lung-landscapes@6
—cohortA10.799
6BS_74G5K7JF
brain-umap@2
Supratentorial Ependymoma—0.796
7EA6A086B-F655-47E8-9E70-8A2D36FC2AE1
brain-umap@2
——0.794
8SRR650201
bladder-landscape@3
——0.787
9MDT-AP-1122
medullo-epn-umap@date-based
MedMedulloblastoma0.782
10BS_TJTEF70D
brain-umap@2
high-grade glioma—0.779

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.440Inavolisib— uncovered
PROTEIN_SECRETION0.430Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.380Remibrutinib— uncovered
TGF_BETA_SIGNALING0.320Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.300Inavolisib— uncovered
ADIPOGENESIS0.260Inavolisib— uncovered
E2F_TARGETS0.260Inavolisib— uncovered
G2M_CHECKPOINT0.240Inavolisib— uncovered
MYC_TARGETS_V10.230Inavolisib— uncovered
NOTCH_SIGNALING0.220Inavolisib— uncovered
UV_RESPONSE_DN0.200Inavolisib— uncovered
DNA_REPAIR0.190Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.190Inavolisib— uncovered
ANDROGEN_RESPONSE0.180Inavolisib— uncovered
FATTY_ACID_METABOLISM0.180Inavolisib— uncovered
MYC_TARGETS_V20.160Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.160Idelalisib— uncovered
P53_PATHWAY0.150Idelalisib— uncovered
MITOTIC_SPINDLE0.140Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.110Idelalisib— uncovered